Cempra Pharmaceuticals (United States)

Antibacterial discovery and development—the failure of success?

Prabhavathi Fernandes · Nature Biotechnology · 2006 · 245 citations

Antimicrobial Drug Discovery, Antimicrobial Susceptibility, Antibiotics +9

Binding and Action of CEM-101, a New Fluoroketolide Antibiotic That Inhibits Protein Synthesis

Beatriz Llano-Sotelo, J.A. Dunkle, Dorota Klepacki et al. · Antimicrobial Agents and Chemotherapy · 2010 · 147 citations · Full text

Drug Target, Protein Assembly, Molecular Biology +20

Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL)

Carlos M. Barrera, Analía Mykietiuk, Hristo Metev et al. · The Lancet Infectious Diseases · 2016 · 100 citations

Antimicrobial Stewardship, Antibiotics, Community-acquired Bacterial Pneumonia +8

<i>In Vitro</i> Activity of the New Fluoroketolide Solithromycin (CEM-101) against a Large Collection of Clinical Neisseria gonorrhoeae Isolates and International Reference Strains, Including Those with High-Level Antimicrobial Resistance: Potential Treatment Option for Gonorrhea?

Daniel Golparian, Prabhavathi Fernandes, Makoto Ohnishi et al. · Antimicrobial Agents and Chemotherapy · 2012 · 94 citations · Full text

Randomized, Double-Blind, Multicenter Phase 2 Study Comparing the Efficacy and Safety of Oral Solithromycin (CEM-101) to Those of Oral Levofloxacin in the Treatment of Patients with Community-Acquired Bacterial Pneumonia

David Oldach, Kay Clark, Jennifer Schranz et al. · Antimicrobial Agents and Chemotherapy · 2013 · 78 citations · Full text